Structure Therapeutics Inc. 8-K

What Happened

• Structure Therapeutics announced on March 16, 2026 (8‑K) positive topline results from its Phase 2 ACCESS II trial of once‑daily oral GLP‑1 receptor agonist aleniglipron. The randomized, double‑blind, placebo‑controlled 44‑week study enrolled 85 adults with overweight or obesity and evaluated target doses of 120 mg, 180 mg and 240 mg.
• At 44 weeks, mean percent change in body weight versus baseline was -13.6% (120 mg), -15.3% (180 mg) and -15.0% (240 mg) versus +1.1% for placebo. Placebo‑adjusted reductions were -14.7%, -16.3% and -16.0% respectively (all p<0.0001). The company also reported safety/tolerability consistent with the GLP‑1 class; most common adverse events were gastrointestinal (nausea, vomiting).

Key Details

• Study size and design: ACCESS II randomized 85 participants; 44‑week duration with 4‑week titration up to 120/180/240 mg.
• Efficacy at 44 weeks: placebo‑adjusted mean weight loss of ~14.7%–16.3% across active dose arms (p<0.0001).
• Body composition study (n=71): using a lower 2.5 mg starting dose, interim data at ~20 weeks showed a 6.8% weight loss and improved tolerability vs prior 5 mg starts.
• Safety and development: aleniglipron tested in >625 participants across studies with no reported drug‑induced liver injury, no persistent liver enzyme elevations, and no QTc prolongation to date. A Type B End‑of‑Phase 2 meeting with FDA is scheduled in Q2 2026; Phase 3 is planned to start in H2 2026 with a 2.5 mg starting titration and doses up to 240 mg under evaluation.

Why It Matters

• These topline Phase 2 results show substantial, statistically significant weight loss signals for an oral GLP‑1 candidate, a potential differentiator versus injectable therapies if results hold in larger trials. Improved tolerability with a lower 2.5 mg starting dose is a key operational finding that the company plans to use in Phase 3 design.
• For investors, the filing signals advancement toward Phase 3 (FDA meeting scheduled) but also includes standard forward‑looking caution: data are topline/interim and may change after full review, and future results, regulatory outcomes and commercial success are not guaranteed.